Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of
cells commonly termed “cancer stem cells” that has been proposed to be a strong driving …

DNA methylation is a stable epigenetic mark that can be inherited through multiple cell
divisions. During development and cell differentiation, DNA methylation is dynamic, but …

Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …

Cancer undergoes “immune editing” to evade destruction by cells of the host immune
system including natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Current …

Investigation into intratumoral heterogeneity (ITH) of the epigenome is in a formative stage.
The patterns of tumor evolution inferred from epigenetic ITH and genetic ITH are remarkably …

Ovarian cancer (OC) is one of the most common malignant tumors in women. OC is
associated with the activation of oncogenes, the inactivation of tumor suppressor genes, and …

Background Platinum based agents—cisplatin and carboplatin in combination with taxanes
are used for the treatment of ovarian cancer (OC) patients. However, the majority of OC …

DNA methylation plays a pivotal role in the etiology of cancer by mediating epigenetic
silencing of cancer-related genes. Since the relationship between aberrant DNA methylation …